GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » PB Ratio

CMMB (Chemomab Therapeutics) PB Ratio : 2.01 (As of Mar. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-03), Chemomab Therapeutics's share price is $1.74. Chemomab Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $0.87. Hence, Chemomab Therapeutics's PB Ratio of today is 2.01.

The historical rank and industry rank for Chemomab Therapeutics's PB Ratio or its related term are showing as below:

CMMB' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 4.78
Current: 2

During the past 4 years, Chemomab Therapeutics's highest PB Ratio was 4.78. The lowest was 0.00. And the median was 0.00.

CMMB's PB Ratio is ranked better than
56.77% of 1286 companies
in the Biotechnology industry
Industry Median: 2.385 vs CMMB: 2.00

During the past 3 years, the average Book Value Per Share Growth Rate was 6.80% per year.

During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Chemomab Therapeutics was 6.80% per year. The lowest was 6.80% per year. And the median was 6.80% per year.

Back to Basics: PB Ratio


Chemomab Therapeutics PB Ratio Historical Data

The historical data trend for Chemomab Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics PB Ratio Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- 1.28 0.98 0.43

Chemomab Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.43 0.83 1.31 1.82

Competitive Comparison of Chemomab Therapeutics's PB Ratio

For the Biotechnology subindustry, Chemomab Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemomab Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's PB Ratio falls into.



Chemomab Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Chemomab Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=1.74/0.865
=2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Chemomab Therapeutics  (NAS:CMMB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Chemomab Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemomab Therapeutics Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Executives
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor director, 10 percent owner, officer: Chief Executive Officer 15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen director C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel officer: Chief Medical Officer 672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley director TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles director 5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin officer: Executive VP, CFO & COO 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost director, officer: Chief Executive Officer ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish director C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel 10 percent owner 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal officer: Chief Financial Officer 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon officer: Chief Medical Officer 12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629